Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Efficacy, Safety, and Tolerability of AXA1125 in Subjects With Fatigue-Predominant Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Efficacy, Safety, and Tolerability of AXA1125 in Subjects With Fatigue-Predominant Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AXA 1125 (Primary)
  • Indications Fatigue; Post acute COVID 19 syndrome
  • Focus Therapeutic Use
  • Sponsors Axcella Health

    • Most Recent Events

    • 24 May 2023 Results presented at the 119th International Conference of the American Thoracic Society
    • 17 Apr 2023 According to an Axcella Health media release, data from this study presented by Dr. Lucy E.M. Finnigan at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), 2023.
    • 17 Apr 2023 Results presented in an Axcella Therapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top